Physician profile
Robert E Mcclure
NPI 1447253786
$3,002.67
in general payments reported to CMS, 2019-2025
31 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $677 · 2021: $444 · 2022: $227 · 2023: $459 · 2024: $285 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $473.35 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $414.84 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $264.22 | 2019-2022 | |
| Pfizer INC. | $247.15 | 2019-2025 | |
| Lilly USA, LLC | $245.87 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $241.57 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $240.75 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $139.93 | 2019-2021 | |
| Amarin Pharma, INC. | $108.96 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.54 | 2019-2024 | Jardiance |
| Amgen INC. | $73.89 | 2020-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.25 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $45.59 | 2024 | Crysvita |
| Mylan Specialty L.P. | $44.47 | 2022-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $44.02 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $31.69 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $30.92 | 2025 | Endurant Iis |
| Astellas Pharma US INC | $27.62 | 2019 | |
| Gilead Sciences, INC. | $24.34 | 2024 | |
| Corcept Therapeutics | $19.01 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $18.74 | 2022 | |
| Viatris Specialty LLC | $17.61 | 2025 | Yupelri |
| Dexcom, INC. | $17.37 | 2025 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $15.21 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.13 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $12.97 | 2023 | |
| Allergan, INC. | $12.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.83 | 2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $12.41 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.56 | 2019 | |
| Metacel Pharmaceuticals LLC | $7.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.